Gilteritinib hemifumarate

Gilteritinib hemifumarate purchased from MedChemExpress. Usage Cited in: Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]

Customer Validation
Kaplan-Meier survival curve of mice engrafted with Cd45.1 WT cells and bone marrow cells from symptomatic Npm1Lox-C-Flt3GL-ITD mice. Mice were treated with control chow (grey). placed on a Tamoxifen chow diet (red) for 4 weeks, or treated with gilteritinib (p.o.; 60 mg/kg; three times weekly) for 4 weeks (green); treatment was withdrawn at the indicated time point (n=7–10).

Gilteritinib hemifumarate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2024 Jul;5(7):1082-1101. [Abstract]

Customer Validation
Growth inhibition, IC50 and AUC values, of OCI-AML2 cells transduced with either a non-targeting control, two PIK3CG-directed, or two PIK3R5-directed sgRNAs and treated with increasing concentrations of the FLT3 inhibitors, Gilteritinib (10-1000 nM) and Sorafenib (10-1000 nM), or KIT inhibitors, Amuvanib and Telatinib

Gilteritinib hemifumarate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Sep 16;8(37):eabp9005. [Abstract]

Customer Validation
Knockdown of CDK9 or DHODH but not CDK7 with shRNA increases the frequency of apoptotic AML cell lines with Gilteritinib. Parental, scrambled, or gene-targeting shRNA-stable MOLM-13 cells were treated with Gileritinib (8 nM ; 120 h) and stained with annexin V/PI for flow cytometry analysis.

Gilteritinib hemifumarate purchased from MedChemExpress. Usage Cited in: Sci Adv. 2022 Sep 16;8(37):eabp9005. [Abstract]

Customer Validation
The relative expressions of selected genes in pro-proliferation/anti-apoptosis, OXPHOS, purine de novo biosynthesis, mevalonate metabolism, glycolysis, and glutamine transport pathways and PTK2, KRT18, and PRMT5 in scrambled, shCDK9-, shPRMT5-, and shDHODH-stable MOLM-13 in response to vehicle or Gilteritinib (8 nM; 48-96 h) treatment were measure by real-time PCR with respect to GAPDH. Values are expressed as fold changes (means ± SEM, n = 3) relative to vehicle-treated scrambled cells. *P < 0.05 and **P < 0.01. Treatment durations are indicated.

Gilteritinib hemifumarate purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2020 Jun 17:20:250. [Abstract]

Customer Validation
MV4-11 and MOLM13 cells are treated with Gilteritinib (2.5 nM) and/or ATO (0.5 µM) for 48 h and protein levels of P-FLT3 and FLT3 are determined by Western blot. Gilteritinib exhibits a strong inhibition on the phosphorylated FLT3 even at a low concentration of 2.5 nM, but had little effect on total FLT3 and USP10.

Gilteritinib hemifumarate purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2020 Jun 17:20:250. [Abstract]

Customer Validation
Proliferation assay demonstrates that FLT3-ITD mutant cells (MV4-11 and MOLM13) are more sensitive to Gilteritinib compared with FLT3-WT cells (THP1 and HL60).

Gilteritinib hemifumarate purchased from MedChemExpress. Usage Cited in: Science. 2017 Dec 1;358(6367):eaan4368. [Abstract]

Customer Validation
Western blot readout for phospho-SMAD in U-2 OS cells treated with inhibitor Gilteritinib (1 µM; 30 min) in the presence or absence of BMP2. S